I've been researching a biotech company lately that is likely to become a big player in the smoking cessation market, in which GSK's Nicoderm CQ and Nicorette are among the most recognized names. I figured other people who invest/follow GSK might be interested.
The company's called 22nd Century (ticker XXII), and it has 98 patents in 79 countries for the genetic pathway controlling nicotine production in tobacco. They're in FDA trials to get a virtually nicotine-free tobacco on the market as a smoking cessation aid, and so far the research has been very promising. They were featured in the New York Times, were assigned a $5 one-year price target by Elmer Piros (rated #1 biotech analyst by the Wall Street Journal) of Rodman & Renshaw, and have had some big deals with the U.S. government itself (NIDA, part of the NIH).
I think it's worth looking into for anyone interested in the biotech/pharmaceutical sector, especially for smoking cessation/tobacco. Just wanted to get some more eyeballs on the stock, since right now there isn't much volume. Definitely a good long opportunity.